Datapoint: Jardiance Catches Up With Farxiga in Heart Failure

The FDA last week approved Eli Lilly and Boehringer Ingelheim’s SGLT2 inhibitor Jardiance for the treatment of heart failure in patients with reduced ejection fraction, regardless of diabetic status. Jardiance is the second SGLT2 inhibitor to snag this indication, behind AstraZeneca’s Farxiga. For the treatment of chronic heart failure under the pharmacy benefit, Farxiga holds covered or better status for 92% of all insured lives.

SOURCE: MMIT Analytics, as of 8/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 11

Datapoint: Sentara to Open Community Care Centers, Launch New Model

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today